Stocktoria
Bodhi Tree Biotechnology Inc BDTB
Bodhi Tree Biotechnology Inc (BDTB) earns a Piotroski F-score of 0/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $17,000 at a -880.4% net margin.
How it ranks in Services · percentile among 1013 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 0/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| BDTB | Bodhi Tree Biotechnology Inc | 0/9 | — | — | — |
| GFLT | GenFlat Holdings, Inc. | 4/9 | — | — | — |
| BLNC | Balance Labs, Inc. | 2/9 | — | — | — |
| RDSC | Radiant Strategies Corp | — | -6.6 | — | — |
| YSGL | Yellowstone Group Ltd. | 5/9 | 1.03 | — | — |
| PHCI | Panamera Holdings Corp | 4/9 | — | — | — |
| AUC | ATIF Holdings Ltd | 3/9 | — | — | — |
FAQ
Is BDTB financially healthy?
Bodhi Tree Biotechnology Inc's Piotroski F-score is 0/9 (8–9 is excellent, 0–3 weak).
Does BDTB pay a dividend?
No, Bodhi Tree Biotechnology Inc does not currently pay a dividend.
How profitable is BDTB?
In FY2025, Bodhi Tree Biotechnology Inc had a net margin of -880.4% and a return on equity of -125.6%.
Is BDTB a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Bodhi Tree Biotechnology Inc: a Piotroski F-score of 0/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-09-30. Facts plus Stocktoria's own computed scores — not investment advice.